FOXO3 and pancreatic neoplasm: These clinical observations suggest that the expression of FOXO3a and miR-4259 positively correlates with recurrence-free survival outcomes in pancreatic cancer patients treated with gemcitabine and inversely correlates with the expression of LDHA and CSC markers within this cohort.